In conclusion, our in silico study suggested that NSP3 is an important onco-immunological biomarker encompassing the tumor microenvironment, disease staging, and prognoses in lung cancer and could serve as an attractive target for cancer therapies. The gene discussed is SH2D3C; the disease is lung carcinoma.